MedTrace Logo

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

NCT03027934 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-07-15

No results posted yet for this study

Summary

The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in a cross-over design.

Conditions

Interventions

DRUG

Ticagrelor

Ticagrelor, 90mg twice daily

DRUG

Prasugrel

Prasurgrel, 10mg once daily

Sponsors & Collaborators

  • CirQuest Labs, LLC

    lead OTHER

Principal Investigators

  • Jayaprakash Kotha · CirQuest Labs

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2017-10-31
Completion
2017-10-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03027934 on ClinicalTrials.gov